Skip to main content

Table 7 Increase in the relative frequency (%), relative to placebo, in different outcomes, the corresponding number needed to treat (NNT) and 95% CIs calculated using a normal approximation. - Data were not available. Data from different studies were pooled when the same outcomes from the same treatments were available and when they referred to doses and/or regimens approved in Brazil

From: The Brazilian Society of Rheumatology guidelines for axial spondyloarthritis – 2019

OutcomePASI50PASI75PASI90
Follow-up time (weeks)
242424
Drug%NNT (95% CI)%NNT (95% CI)%NNT (95% CI)
Infliximab [195]66.71.5 (1.3–1.8)58.81.7 (1.4–2.1)38.42.6 (2.0–3.6)
Etanercept [196, 197]27.03.7 (2.6–6.3)20.84.8 (3.5–7.8)
Adalimumab [198]62.51.5 (1.2–1.8)58.81.7 (1.4–2.2)41.72.4 (1.9–3.3)
Golimumab [199]66.71.5 (1.3–1.8)55.51.8 (1.6–2.2)32.23.1 (2.4–4.3)
Certolizumab pegol [200]45.52.2 (1.7–2.9)45.52.2 (1.8–2.8)35.72.8 (2.2–3.7)
Secukinumab [201, 202]37.02.1 (1.8–2.6)35.72.7 (2.2–3.4)